# Study to Determine the Antibody Response to 500µg G17DT in Treatment of Patients With Gastric Cancer

> **NCT02450032** · PHASE2 · COMPLETED · sponsor: **Cancer Advances Inc.** · enrollment: 12 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **BIOLOGICAL:** G17DT

## Key facts

- **NCT ID:** NCT02450032
- **Lead sponsor:** Cancer Advances Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-02
- **Primary completion:** 2001-05
- **Final completion:** 2001-05
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2015-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02450032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02450032, "Study to Determine the Antibody Response to 500µg G17DT in Treatment of Patients With Gastric Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02450032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*